A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors
Phase of Trial: Phase I
Latest Information Update: 28 Oct 2018
At a glance
- Drugs RO 7198457 (Primary) ; Atezolizumab
- Indications Tumours
- Focus Adverse reactions
- Sponsors Genentech
- 13 Apr 2018 Planned number of patients changed from 572 to 567.
- 16 Mar 2018 Planned End Date changed from 11 Sep 2020 to 29 Oct 2020.
- 11 Dec 2017 Planned initiation date changed from 7 Dec 2017 to 30 Dec 2017.